ratio of ET-1 over proET-1 ( ET-1/proET-1) was significantly higher than in patients without hypertension. Background. The pathogenesis of rHuEpo-induced hypertension in haemodialysis (HD) patients still In addition, the increase in ET-1 levels was significantly greater in patients with interdialysis hypertension, remains uncertain. Endothelin-1 ( ET-1) is produced from proendothelin-1 (proET-1) by an endothelin-while changes in proET-1 level were similar in both hypertensive and non-hypertensive groups. Changes in converting enzyme. Since proET-1 is known to have approximately 1/100 the potency of ET-1 for con-interdialysis MAP (DIDMAP) was significantly correlated with DET-1 during the interdialysis period, but tracting an isolated blood vessel, the change in the activity of endothelin-converting enzyme ( ECE) has not with DproET-1.
ory blood pressure monitoring. Different routes of administration (19 intravenous group, 10 subcutaneous
The positive effects of recombinant human erythrogroup) were compared to a placebo-injected control poietin (rHuEpo) treatment on anaemia in chronic group (10 HD patients) .
renal failure patients have been well documented [1, 2] .
Results. Plasma erythropoietin levels reached maximal
However, complications such as hypertension, thromvalue 5 min after i.v. injection of rHuEpo (13.1±2. 4 bosis of arteriovenous fistula, flu-like symptoms and vs 2780.9±290.1 mU/ml, P<0.01), whereas it was hyperkalaemia can also develop with rHuEpo therapy 6 h in the s.c. group (14.7±3.8 vs 38.9±17.7 mU/ml, [1] [2] [3] . Hypertension is an important complication P<0.05). A significant increase in MAP was noted which affects the overall prognosis of end-stage renal 30 min after rHuEpo injection, which lasted for 3 h in disease (ESRD) patients. Twenty to fifty per cent of the i.v. group. However, no significant changes in ESRD patients treated with rHuEpo are at risk of MAP were noted in patients given rHuEpo subcutanedeveloping a significant rise in blood pressure, even ously. Both the plasma concentrations of proET-1 and with the occurrence of encephalopathy or seizure ET-1 started to increase from 10 min after i.v. rHuEpo [1, 2, 4] . The exact mechanism of rHuEpo-induced administration, with the proET-1 reaching a peak level hypertension in haemodialysis (HD) patients still at 30 min (13.5±7.4 vs 21.6±3.8 pg/ml, P<0.05) and remains uncertain. An imbalance of local endothe ET-1 at 1 h (4.2±2.6 vs 9.9±4.8 pg/ml, P<0.05).
thelial factors such as endothelium-derived relaxation In patients with significant interdialysis hypertension factor and endothelin was postulated as one of the following a single i.v. injection of rHuEpo, the molar possible mechanisms involved in rHuEpo-induced hypertension [5] [6] [7] [8] .
the end of the HD session until the start of the next HD from proET-1 or big endothelin (consisting of 38 session. The mean arterial blood pressure (MAP) was calcuamino acids) by an endothelin-converting enzyme loclated as [systolic blood pressure+(2×diastolic blood ated in the vascular endothelial cell [10] , and proET-1 pressure)]×1/3. All subjects were hospitalized after rHuEpo is an intermediate generated from preproET (203 administration for blood-pressure monitoring and blood amino acid ). Since the potency of proET-1 for con-sampling until the next HD session. tracting an isolated blood vessel is approximately 100
Plasma levels of erythropoietin, ET-1 and proET-1 were times less than ET-1, conversion of proET-1 to the measured at the following time points; immediately before active ET-1 is essential for full biological activity rHuEpo injection at the end of the HD session, and 5, 10 [10] [11] [12] . Alterations in the change in the activity of and 30 min and, 1, 6, 12 and 24 h following rHuEpo injection and before the next HD session. Each blood sample was ECE have been reported to be a factor in the pathoobtained through a sampling port located in the opposite physiology of certain disease states [13] [14] [15] . Increased arm from the vascular access. Plasma concentration of molar ratio of proET-1/ET-1 with disruption of the erythropoietin (Diagnostics System Lab., USA), ET-1 endothelin regulatory system appeared to accelerate (Nichols Institute, USA) and proET-1 (Nichols Institute, the development of pre-eclampsia [13] and an elevated USA) were measured by radioimmunoassay. Blood samples proET-1 level with a normal ET-1 level in diabetic for ET-1 and proET-1 were collected into tubes containing patients with microangiopathy was explained by a aprotinin (500 000 U/l of blood ) and EDTA (1 g/l ). Plasma reduced activity of converting enzyme [14] . How-was centrifuged at −4°C and quickly separated. The samples ever, there has been no study evaluating the role of were extracted with 4% acetic acid and the acetone extract ECE activity in the pathogenesis of rHuEpo-induced was dried with vacuum at 37°C (efficiency 90%). The dried extract was reconstituted and analysed with an RIA using hypertension.
[125I ]endothelin and rabbit antiendothelin. To avoid interas-
The present study was undertaken to ascertain the say variation, all samples were assayed in a single session.
potential role of ECE in rHuEpo-induced hypertension
The sensitivities of the assay for ET-1 and proET-1 were by evaluating the acute effects of a single dose of 2.0 pg/ml and 1.4 pg/ml, respectively. The cross-reactivity of rHuEpo on plasma levels of proET-1 and ET-1 along the assay was as follows: ET-1, 100%; ET-2, 52%; ET-3, with the changes in interdialysis blood pressure by 96%; and 7% with proET-1. 24-h ambulatory blood-pressure monitoring.
Statistics

Subjects and methods
The data are expressed as mean±standard deviation or median. Differences in plasma ET-1 and proET-1 concen-
Patients
trations were compared by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison. Thirty-nine clinically stable HD patients (19 males and 20 Changes in concentrations of erythropoietin, ET-1, proET-1 females) ranging in age from 24 to 67 years (mean 47 years) and blood pressure were compared by Wilcoxon's test at participated in this study. The study was approved by the each time point after rHuEpo administration. Correlation institutional ethics committee and informed consent was between the changes in blood pressure and plasma levels of obtained from each patient. Exclusion criteria were patients ET-1 and proET-1 was analysed by linear regression. Values with uncontrolled hypertension (blood pressure: systolic of P<0.05 were considered to be significant. >160 mmHg and diastolic >100 mmHg) and those taking antiplatelet agents or anabolic steroids. Twenty (54.1%) patients were treated for hypertension with either calcium-
Results
channel blocker (15 cases), a-adrenergic blocker (8 cases), or angiotensin converting enzyme inhibitor (7 cases). The aetiologies of renal failure were chronic glomerulonephritis Patient characteristics (13 patients) , diabetic nephropathy (10 patients), hyper-
The clinical characteristics of the subjects are shown tensive nephrosclerosis (9 patients), polycystic kidney disease in Table 1 . There were no significant differences in (2 patients), renal tuberculosis (1 patient), lupus nephritis (1 patient), and unknown (3 patients). None of these patient age, duration of HD, and blood pressure patients were administered rHuEpo treatment within 1 month among control, i.v., and s.c. groups. Haematocrit, of this study.
blood urea nitrogen, creatinine and lipid profiles were also similar ( Table 2 ), The median values of erythropoStudy protocol ietin in the three group were 12.4, 13.0 and 13.9 mU/ml respectively. The median values for ET-1 and proET-1 Patients were randomized to receive rHuEpo either subcuta-were not different between the three groups.
neously (10 cases) or intravenously (19 cases) and were compared to an intravenous placebo (2 ml of sterile distilled Plasma erythropoietin levels after rHuEpo water) control group (10 HD patients). A single dose of rHuEpo (RecormonA, erythropoietin-b, Choongwai Co, Figure 1 illustrates the changes in the plasma erythroSeoul, Korea) (100 U/kg body weight) was injected at the poietin level in the rHuEpo-injected patients and conend of each dialysis session. Ambulatory blood pressure trol group. In the i.v. rHuEpo group, the erythropoietin monitoring was performed using a non-invasive ambulatory level rose abruptly and reached a peak at 5 min, blood pressure monitor (BP3, Mediana, USA). Systolic and whereas in the s.c. group, the peak level was obtained diastolic blood pressure with pulse rate were recorded every significant changes in plasma ET-1 levels in control and the s.c. rHuEpo group ( Figure 2 ). Similar findings Values are mean±SD; a % of patients on antihypertensive medica-were observed for proET-1 (Figure 3) . The proET-1 tions at the time of study; SBP, systolic blood pressure; DBP, level rose significantly 10 min after injection, peaking diastolic blood pressure.
at 30 min and remained elevated up to 3 h after rHuEpo in the i.v. group only. patients. In Figure 5 , molar ratio of ET-1 over proET-1
( ET-1/proET-1) was plotted against each time point of blood sampling after rHuEpo administration.
aValues are mean±SD; Hct, haematocrit; BUN, blood urea nitrogen;
Cr, creatinine; Chol, cholesterol; Tg, triglyceride; Epo, erythro-ET-1/proET-1 ratio significantly increased after i.v. poietin; ProET-1, proendothelin-1; ET-1, endothelin-1; bValues are rHuEpo injection compared to baseline value and medians.
reached a peak at 1 h of rHuEpo. Thereafter, ET-1/proET-1 gradually returned to the pre-rHuEpo value. In patients with significant interdialysis hypererythropoietin in the i.v. group was 2780.9 mU/ml, which was significantly higher compared to the value tension, ET-1/proET-1 ratios at 30 min and 1 h were significantly higher compared to the patients without of 38.9 mU/ml in the s.c. group. Plasma erythropoietin level fell gradually after an abrupt peak in the i.v. hypertension. The changes in proET-1 (DproET-1) and ET-1 (DET-1) are compared in Table 3 . DET-1 and changes in interdialysis MAP, DIDMAP, represent the difference between the mean value of all measurment during the interdialysis period and the values prior to i.v. rHuEpo injection of the preceding dialysis session. DET-1 was significantly greater in the group of patients with DIDMAP>10 mmHg than in those with DIDMAP<10 mmHg (7.4 vs 3.2 pg/ml, P<0.05). However, the changes in DproET-1 were similar in both patient groups. Interdialysis weight gains were similar in both groups, and therefore a difference in volume status was unlikely to be a cause of the There was no significant correlation between DIDMAP and DproET-1 in the i.v. rHuEpo patients ( Figure 6 ).
Discussion
In contrast, there was a significant positive correlation between DIDMAP and DET-1 in the i.v. rHuEpo group with a r-value of 0.78 ( Figure 7) . We could not The pathogenesis of rHuEpo-induced hypertension in HD patients still remains uncertain. Increased blood find any significant correlation between DproET-1 and DET-1.
viscosity and loss of hypoxic vasodilatation subsequent aValues are mean±SD; MAP, mean arterial blood pressure; bDIDMAP, Changes in MAP during interdialysis period=MAP during interdialysis period-postHD, preEpo MAP of preceding dialysis session; cP<0.05 vs DIDMAP<10 mmHg group. erythropoietin level after rHuEpo administration. Our study revealed that there were no changes in both blood pressure and the levels of ET-1 in the s.c. rHuEpo group, which is concordant with the result of others [6, 30] . The ratio of ET-1/proET-1, a surrogate marker of ECE activity, increased significantly after rHuEpo administration only in the patients with significant interdialysis hypertension and its value was significantly higher than in patients without a significant elevation in blood pressure. In both groups the ratio of ET-1/proET-1 was highest at 1 h following rHuEpo administration, which coincided with the maximal their changes in proET-1 were similar ( Table 3) . Moreover, changes in interdialysis blood pressure was positively correlated with changes in ET-1 ( Figure 7 ) to the correction of anaemia, and mobilization of vascular cytosolic calcium [16] [17] [18] are the postulated whereas it was not correlated with DproET-1 ( Figure 6 ). These findings suggest that ECE activity pathogenetic mechanisms. Increased circulating levels of vasoactive substances including endothelin have may play a role in the development of hypertension following acute injection of rHuEpo in HD patients. also been reported to play a role in the increase in blood pressure in rHuEpo-treated patients [19, 20] . Intravenous rHuEpo may stimulate the production or release of proET-1 from vascular endothelial cells, with Incubation with rHuEpo has been shown to increase the ET-1 synthesis in endothelial cells from human hypertension developing only in a specific group of patients who have an increased activity of ECE umbilical vein [21] and bovine pulmonary artery [7] . However, there are controversies regarding a direct resulting in the elevated ET-1 and blood pressure. It should be stressed that this interpretation is very vasoconstrictor effect of rHuEpo [17, 21, 22] . Bode-Bö ger et al. [21] demonstrated that rHuEpo had presumptive since direct measurement of ECE activity was not carried out and any differences in ECE activity no direct vasoconstrictor effect, but it enhanced noradrenaline-induced vasocontraction while others in relation to the interdialysis hypertension has not been proved. Other possibilities include preferential observed constant contraction of caudal artery rings with rHuEpo [22] . In the study of Bode-Bö ger et al., excretion of ET-1 from endothelial cells to the circulation or diminished break-down of ET-1 in patients the selective endothelin-A receptor antagonist partly inhibited rHuEpo-induced enhancement of vascular with interdialysis hypertension. To elucidate a potential role of ECE in rHuEpo-induced hypertension, responsiveness to noradrenaline [21] .
Impact of rHuEpo on plasma ET-1 level and its experiments with ECE blocker are necessary. After i.v. rHuEpo, plasma erythropoietin concentrarelation with rHuEpo-induced hypertension remains controversial. Most of the previous studies revealed tion remained high for about 6-12 h, whereas the effect on ET-1 and blood pressure lasted only 3-6 h. The that chronic administration of rHuEpo was not associated with an increase in ET-1 levels in predialysis renal initial non-physiological rise in plasma erythropoietin level seems to be important in raising blood pressure; failure [23, 24] , HD [25, 26 ] , and CAPD [27] patients. Takahashi et al. [28] reported that plasma ET-1 level the exact cause for this discrepancy in the time course is unclear. The other limitation of this study was that in HD patients increased only in patients whose MAP increased by more than 10 mmHg after 8 weeks of it is not a double-blind cross-over study. However, it would be rather difficult to keep various clinical pararHuEpo. Our data, as well as another report [6 ] , clearly indicate that a single intravenous injection of meters such as interdialytic period, fluid status, and medications similar between two occasions of rHuEpo rHuEpo can acutely increase both blood pressure and plasma ET-1. However, Hon et al. [29] reported no or placebo administration. Therefore we selected subjects with similar clinical characteristics to overcome changes in blood pressure and ET-1 concentration after a single i.v. rHuEpo injection in their double-this problem.
In conclusion, plasma levels of proET-1 and ET-1 blind cross-over study with nine HD patients. The observed differences in blood pressure and ET-1 levels increase after a single intravenous administration of rHuEpo which can be associated with an acute elevaafter a single injection of rHuEpo may be due to the timing of blood pressure and ET-1 measurements. We tion of blood pressure in haemodialysis patients. Molar ratios of ET-1/proET-1 at the time of maximal incremeasured blood pressure after HD, while Hon et al. performed this measurement prior to HD. In addition, ment of blood pressure were higher in patients with a significant interdialysis hypertension, suggesting a they administered a lower amount of rHuEpo (50 U/kg) and there was no information regarding plasma possibility of potential role of ECE in the genesis of 
